World Pharmaceutical Frontiers’ Post

At the 17th Drug Discovery Strategic Summit 2024, Ziaurrehman Tanoli presented a compelling exploration into the "In-silico methods and tools for drug repurposing." His talk focused on how computational approaches, particularly in-silico techniques, are reshaping the landscape of drug discovery and repurposing.The session highlighted the growing importance of integrating computational approaches to streamline the drug discovery process. With such engaging sessions, DDSS continues to serve as a pivotal platform for knowledge-sharing and innovation in the field of drug discovery. #DDSS #DrugRepurposing #PharmaInnovation #InSilicoMethods #Pharmaceuticals #Biopharma

What's in it for emerging biotechs when partnering with a CDMO for early stage development? James Berrie and Raymond Donninger discuss how the expertise, efficiency and scalability of a CDMO is crucial for efficiently and cost-effectively delivering new therapeutic candidates for an investigational new drug and first-in-human trials. Read the full interview in Pharma Network here: https://lnkd.in/dKXyWrCy #AHealthierWorld #PharmaceuticalManufacturing #CDMO #Biotech #EarlyStageDevelopment

Thoughts on this? >> Otsuka makes $800M acquisition of Jnana Therapeutics to expand small molecule drug discovery >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #biotech #productmarketing

The FDA’s Center for Drug Evaluation and Research (#CDER) approved 55 new drugs in 2023. Although that’s the second-highest count in the past 30 years, it doesn’t account for the many others that didn’t make the cut. To be deemed a “success,” a new drug must make it through five critical phases: 1) discovery and development, 2) preclinical research, 3) clinical research, 4) FDA review, and lastly, 5) post-market safety monitoring. Our blog explores the intricacies of every phase and discusses how a #CDMO partner can help #biotech and #pharma companies navigate their way through while ensuring compliance with regulatory standards. You can read the blog here: http://spr.ly/6041XqdDZ

The FDA’s Center for Drug Evaluation and Research (#CDER) approved 55 new drugs in 2023. Although that’s the second-highest count in the past 30 years, it doesn’t account for the many others that didn’t make the cut. To be deemed a “success,” a new drug must make it through five critical phases: 1) discovery and development, 2) preclinical research, 3) clinical research, 4) FDA review, and lastly, 5) post-market safety monitoring. Our blog explores the intricacies of every phase and discusses how a #CDMO partner can help #biotech and #pharma companies navigate their way through while ensuring compliance with regulatory standards. You can read the blog here: http://spr.ly/6046Xqj4j

💡 AI in Drug Discovery is Accelerating Innovation! 🧬🤖 The global artificial intelligence (AI) in drug discovery market, valued at USD 3.00 billion in 2022, is expected to reach USD 7.94 billion by 2030, growing at a CAGR of 12.2%. AI is helping pharmaceutical companies discover new drugs faster and more accurately, transforming the entire healthcare landscape. With North America dominating the market at 69.33%, the region is driving significant innovation in this space. Interested in how #AI is advancing drug discovery? Read the full report here 👉 AI in Drug Discovery Market Overview https://lnkd.in/egNzJtgY #ArtificialIntelligence #AIinHealthcare #DrugDiscovery #HealthcareInnovation #PharmaceuticalIndustry #AIMarketTrends

🔬 Radiolabeled Drugs: The Undercover Agents of Pharma 🌟 Exploring the body's mysteries, radiolabeled drugs 🧬 serve as pharma's detectives 🕵️♂️. They embark on a mission 🚀, stealthily navigating to their targets 🎯, with PET and SPECT imaging capturing their every move in real-time 📡. This journey unveils invaluable insights 📊 into drug efficacy and distribution, revolutionizing drug development 🌐. #RadiolabeledDrugs #PharmaInnovation #DrugEfficacy #TargetedTherapy #MolecularImaging

Thoughts on this? >> Otsuka makes $800M acquisition of Jnana Therapeutics to expand small molecule drug discovery >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech

Discover how GenAI is transforming drug discovery, clinical trials, and personalized medicine. Axtria’s latest article dives into the future of pharmaceuticals with innovative AI and GenAI-driven solutions: https://bit.ly/3VqXJQR #ClinicalTrials #Pharma #DrugDiscovery #GenerativeAI

Thrilled to be featured in Pharmaceutical Executive, discussing a topic I'm deeply passionate about: the AI revolution in drug discovery.   This piece explores the broader implications of AI in biopharma - how TITAN-X is reshaping timelines, reducing development costs, improving success rates, and transforming patient outcomes with the next wave of potential blockbuster drugs targeting new mechanisms of action.    I invite you to read the full article at the link below.